Cardiac dysfunction associated withtrastuzumab Review uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Breast Neoplasms
  • Genes, erbB-2
  • Heart Diseases

abstract

  • The HER2/neu gene is amplified in approximately 25% of breast cancers, leading to HER2 protein overexpression and shortened overall survival and time to relapse. Trastuzumab is a humanised, monoclonal antibody against HER2, which improves survival for women with metastatic HER2-overexpressing breast cancer and reduces the risk of recurrence in women with early stage HER2-overexpressing breast cancer. Cardiac toxicity was an unexpected finding in the pivotal Phase III trial leading to the approval of trastuzumab, and prospective cardiac monitoring has, therefore, been incorporated into more recent clinical trials of trastuzumab. This article reviews the cardiac toxicity findings in key trastuzumab clinical trials and clinical characteristics of trastuzumab-associated cardiac toxicity.

publication date

  • September 2006

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1517/14740338.5.5.619

PubMed ID

  • 16907652

Additional Document Info

start page

  • 619

end page

  • 29

volume

  • 5

number

  • 5